COMPUTERS IN BIOLOGY AND MEDICINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2022-10-02 ms4000001680289394

偏重的研究方向：数据挖掘
经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓

51 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2023-01-15 ms1000001354699907 来自上海

偏重的研究方向：医学临床数据;Biology;数据挖掘
经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。

41 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2022-03-24 124a8eb2m19暂无昵称

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：医学临床数据;数据挖掘
经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！

68 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2024-01-24 ms3000002100323158 来自山东省

偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic
经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review

21 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2022-10-26 719523476

投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。

2 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2023-12-05 Jacinth 来自广东省

偏重的研究方向：数据挖掘
经验分享：请问这个杂志with editor一般要多久才有结果？

27 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2023-10-22 287119938 来自湖北省

为啥DIP两三周了也不拒稿？

26 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2023-03-13 ms3000000286492025 来自江苏省

一个月从with editor变成了decision in process，是不是被拒了

44 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2023-02-18 ms8000000941284145 来自山东省

偏重的研究方向：Biology;数据挖掘
经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!

44 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091476, encodeId=f39120914e65e, content=偏重的研究方向：数据挖掘 经验分享：昨天投稿，今天就“Decision in process ” ～是准备直接退稿嘛？😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sun Oct 02 15:41:25 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110351, encodeId=f55e21103516e, content=偏重的研究方向：医学临床数据;Biology;数据挖掘 经验分享：生信分子分型，工作量尚可。1-13submitted，1-13with editor，1-15decison in process。这个期刊也有很多生信，内容也不深，还是看运气。后面如果状态跟新，继续跟新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cdf5500642, createdName=ms1000001354699907, createdTime=Sun Jan 15 22:18:29 CST 2023, time=2023-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1205567, encodeId=8ba8120556e1c, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：医学临床数据;数据挖掘 经验分享：一审5个审稿人，几十个审稿意见，但是非常仔细和严谨，返修后半个月二审，因为一个审稿人还是要求补实验，所以又返修，但是返修后给找了另一个审稿人6，又有一部分意见，返修后，直接接收。杂志编辑相当认真，尤其是审稿人，标点符号、语法等全部都能指出，现在即使影响因子6.133，Q1区，感觉非常不错，强烈推荐！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5752504961, createdName=124a8eb2m19暂无昵称, createdTime=Thu Mar 24 14:09:29 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183588, encodeId=72a121835889b, content=偏重的研究方向：Biology;Computational Biomechanics;Orthopaedic 经验分享：请问这个杂志审稿多久啊，我从11月3号under review，到现在一直是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0bb9155553, createdName=ms3000002100323158, createdTime=Wed Jan 24 01:26:36 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2096294, encodeId=4892209629474, content=投了2周了还是with editor。想问下是不是每个作者收到确认邮箱后，都要确认了编辑才会处理呢？有点忐忑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0764859705, createdName=719523476, createdTime=Wed Oct 26 16:44:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2173073, encodeId=d38021e3073f2, content=偏重的研究方向：数据挖掘 经验分享：请问这个杂志with editor一般要多久才有结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Dec 05 16:26:44 CST 2023, time=2023-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164270, encodeId=b38821642e0f7, content=为啥DIP两三周了也不拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=024e2688919, createdName=287119938, createdTime=Sun Oct 22 22:25:25 CST 2023, time=2023-10-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2119278, encodeId=6b7021192e800, content=一个月从with editor变成了decision in process，是不是被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ccd8586034, createdName=ms3000000286492025, createdTime=Mon Mar 13 22:51:22 CST 2023, time=2023-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115266, encodeId=e9cf211526685, content=偏重的研究方向：Biology;数据挖掘 经验分享：做了一篇泛癌+单基因表型验证的，工作量一般。是在不想投Frontiers了。求问各位大佬：是投这里稳还是投computational and structual biotechnology稳?跪谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7c696163486, createdName=ms8000000941284145, createdTime=Sat Feb 18 15:09:53 CST 2023, time=2023-02-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2196759, encodeId=eef52196e595b, content=很多稿件，3/27排到4371号了，命中率估计很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec9e8516334, createdName=ms3000001519379089, createdTime=Wed Apr 03 11:58:42 CST 2024, time=2024-04-03, status=1, ipAttribution=广东省)]

2024-04-03 ms3000001519379089 来自广东省

很多稿件，3/27排到4371号了，命中率估计很低

11 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务